Read more about ACB’s extensive work in GM and biosafety

Push back against risky and unsafe RNAi GM cassava cultivation in Kenya


An unproven genetically modified (GM) RNAi cassava variety is yet another staple food crop, after maize and banana, on the biotech industry’s agenda for commercial cultivation in Kenya. The brazen lack of safety tests contained in the Kenya Agricultural and Livestock Research Organisation’s (KARLO's) application for cultivation, and disregard for adherence to biosafety best practise and disease resistance, has galvanised civil society and farmer organisations to demand reinstatement of the ban on GMOs.  

ACB raises concerns on GM Covid-19 vaccine trials for SA, calls for transparency & public hearings

Civil Society Statement

Clique aqui para a versão portuguesa

Por favor, haga clic aquí para el español

The African Centre for Biodiversity (ACB) has made a submission to the Registrar of GMOs in South Africa, following an application made by Professor Shabir Ahmed Madhi, from the Respiratory and Meningeal Pathogens Research Unit (RMPRU), Chris Hani Baragwanath Academic Hospital, for approval for release of ChAdOx1 nCo-V-19, a genetically modified (GM) vaccine, for clinical phase I/II trials on 2 800 both healthy and HIV-positive adults over a period of 12 months.